These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 26825901)

  • 1. Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis.
    Zhang H; Li X; Huang J; Li H; Su Z; Wang J
    Medicine (Baltimore); 2016 Jan; 95(4):e2575. PubMed ID: 26825901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostanoid therapy for pulmonary arterial hypertension.
    Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of prostacyclin and its analogs in the management of pulmonary arterial hypertension.
    Dandel M; Hetzer R
    Curr Vasc Pharmacol; 2003 Jun; 1(2):171-81. PubMed ID: 15320842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostacyclin therapy for pulmonary arterial hypertension: new directions.
    Gomberg-Maitland M; Preston IR
    Semin Respir Crit Care Med; 2005 Aug; 26(4):394-401. PubMed ID: 16121316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension.
    Budev MM; Minai OA; Arroliga AC
    Drugs Today (Barc); 2004 Mar; 40(3):225-34. PubMed ID: 15148531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostanoid therapy for pulmonary arterial hypertension.
    Strauss WL; Edelman JD
    Clin Chest Med; 2007 Mar; 28(1):127-42; ix. PubMed ID: 17338932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
    Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
    Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
    Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
    Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis.
    Manzi G; Mariani MV; Filomena D; Recchioni T; Papa S; Scoccia G; Badagliacca R; Vizza CD
    Vascul Pharmacol; 2024 Mar; 154():107280. PubMed ID: 38309551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension].
    Osvaldo Cáneva J; Ossés JM
    Medicina (B Aires); 2003; 63(3):233-6. PubMed ID: 12876911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
    Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
    Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled treprostinil: a therapeutic review.
    Channick RN; Voswinckel R; Rubin LJ
    Drug Des Devel Ther; 2012; 6():19-28. PubMed ID: 22291467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostacyclin for pulmonary hypertension.
    Paramothayan NS; Lasserson TJ; Wells AU; Walters EH
    Cochrane Database Syst Rev; 2002; (3):CD002994. PubMed ID: 12137667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
    Gessler T; Seeger W; Schmehl T
    Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.